CTOs on the Move

Delfi Diagnostics

www.delfidiagnostics.com

 
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Tobias Mann
 Vice President of Software Engineering and Information Technology Profile
Timothy McDaniel
 Vice President of Technology Development Profile

Funding

Delfi Diagnostics raised $100M on 01/12/2021

Similar Companies

The Public Health Company

PHC empowers organizations to proactively manage infectious disease risk through global disease forecasting, risk analysis, and practical guidance. PHC was founded by Dr. Charity Dean, and employs a world-class team of public health professionals, tech...

Endocyte Inc

Endocyte Inc is a West Lafayette, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Crescendo Bioscience

Crescendo Bioscience is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intralytix

Intralytix, Inc. is a biotechnology company focused on the production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.

InterveXion Therapeutics

At InterveXion we develop novel products for the treatment of addiction disorders. Since our founding in 2004, our team has been dedicated to providing therapeutic options for patients suffering from the debilitating effects of addiction. We occupy office and laboratory space in the BioVentures Building on the campus of the University of Arkansas for Medical Sciences (UAMS), from whom we licensed our lead technology.